Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow

PURPOSE: Advanced Ewing sarcomas have poor prognosis. They are defined by early relapse (<24 months after diagnosis) and/or by metastasis to multiple bones or bone marrow (BM). We analyzed risk factors, toxicity and survival in advanced Ewing sarcoma patients treated with the MetaEICESS vs. EICES...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiel, Uwe, Wawer, Angela, von Luettichau, Irene, Bender, Hans-Ulrich, Blaeschke, Franziska, Grunewald, Thomas G.P., Steinborn, Marc, Röper, Barbara, Bonig, Halvard, Klingebiel, Thomas, Bader, Peter, Koscielniak, Ewa, Paulussen, Michael, Dirksen, Uta, Juergens, Heribert, Kolb, Hans-Jochem, Burdach, Stefan E.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342601/
https://www.ncbi.nlm.nih.gov/pubmed/27486822
http://dx.doi.org/10.18632/oncotarget.10938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342601/
https://www.ncbi.nlm.nih.gov/pubmed/27486822
http://dx.doi.org/10.18632/oncotarget.10938

Ejemplares similares